UCB First Nine Months Interim Report 2017: Strong 9 ...
(WorldNews Belgium)

Brussels (Belgium), 20 October 2017 - 7:00 (CEST) - regulated information - Revenue increased to EUR 3.3 billion, by 9%; main products grew by 15% to EUR 2.6 billion R&D update: Briviact approved as monotherapy in the U.S. Vimpat approved as monotherapy in Japan and for children as add-on therapy in the EU. Financial outlook 2017 increased: Now revenue expected between EUR4.4 - 4.5bn. REBITDA between EUR1.25 - 1.35bn, Core EPS between EUR4.10 - 4.50 Revenue for the first nine months of 2017 increased to EUR 3.3 billion, by 9% at actual and at constant exchange rates (CER). Adjusted by product divestitures in 2016, the revenue growth was 14%. Core driver of the continued growth are UCB`s main products,...